Progyny, Inc. PGNY
We take great care to ensure that the data presented and summarized in this overview for Progyny, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PGNY
View all-
Black Rock Inc. New York, NY11.8MShares$290 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$248 Million0.0% of portfolio
-
State Street Corp Boston, MA2.91MShares$71.4 Million0.0% of portfolio
-
Thrivent Financial For Lutherans Minneapolis, MN2.16MShares$53 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA1.95MShares$47.9 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.93MShares$47.4 Million0.89% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.89MShares$46.4 Million0.01% of portfolio
-
Fred Alger Management, LLC New York, NY1.71MShares$41.9 Million0.16% of portfolio
-
Fort Washington Investment Advisors Inc1.66MShares$40.7 Million0.2% of portfolio
-
Barclays PLC London, X01.58MShares$38.7 Million0.0% of portfolio
Latest Institutional Activity in PGNY
Top Purchases
Top Sells
About PGNY
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Insider Transactions at PGNY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2026
|
David J Schlanger Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,171
-0.9%
|
$54,275
$25.68 P/Share
|
|
Jan 02
2026
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
6,009
-0.88%
|
$150,225
$25.68 P/Share
|
|
Dec 31
2025
|
Michael E Sturmer PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
33,028
-11.46%
|
$825,700
$25.84 P/Share
|
|
Dec 11
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
459
-0.97%
|
$11,475
$25.5 P/Share
|
|
Dec 04
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
479
-1.0%
|
$11,496
$24.55 P/Share
|
|
Dec 04
2025
|
Allison Swartz EVP, GC |
SELL
Open market or private sale
|
Direct |
530
-0.72%
|
$12,720
$24.59 P/Share
|
|
Dec 04
2025
|
Allison Swartz EVP, GC |
SELL
Payment of exercise price or tax liability
|
Direct |
408
-0.55%
|
$9,792
$24.55 P/Share
|
|
Dec 04
2025
|
Michael E Sturmer PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
7,977
-2.69%
|
$191,448
$24.55 P/Share
|
|
Dec 02
2025
|
Michael E Sturmer PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-0.15%
|
$11,200
$25.27 P/Share
|
|
Dec 02
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
213
-0.44%
|
$5,325
$25.5 P/Share
|
|
Dec 02
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
224
-0.46%
|
$5,600
$25.27 P/Share
|
|
Nov 28
2025
|
Allison Swartz EVP, GC |
SELL
Open market or private sale
|
Direct |
2,398
-3.15%
|
$62,348
$26.87 P/Share
|
|
Nov 28
2025
|
Allison Swartz EVP, GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,352
-1.75%
|
$35,152
$26.7 P/Share
|
|
Nov 18
2025
|
Norman Payson Director |
SELL
Bona fide gift
|
Direct |
50,265
-88.26%
|
-
|
|
Nov 17
2025
|
Mark S. Livingston CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
21,303
-30.58%
|
$532,575
$25.5 P/Share
|
|
Nov 14
2025
|
Norman Payson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,224
+38.88%
|
$36,224
$1.45 P/Share
|
|
Nov 13
2025
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
79,500
+10.46%
|
$1,908,000
$24.29 P/Share
|
|
Nov 10
2025
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
63,813
-9.6%
|
$1,403,886
$22.37 P/Share
|
|
Nov 10
2025
|
Peter Anevski CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+15.83%
|
-
|
|
Nov 10
2025
|
David J Schlanger Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
21,286
-8.13%
|
$468,292
$22.37 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 441K shares |
|---|---|
| Exercise of conversion of derivative security | 36.2K shares |
| Open market or private purchase | 79.5K shares |
| Bona fide gift | 50.3K shares |
|---|---|
| Payment of exercise price or tax liability | 231K shares |
| Open market or private sale | 33.1K shares |